



Contact: Julie Bryant  
VP Business Development and Marketing  
GeneGo, Inc.  
(858) 756 7996  
julie@genego.com

## **CARDIFF UNIVERSITY BECOMES A GENEGO CENTER OF EXCELLENCE**

**St. Joseph, Michigan, April 22nd, 2009** – GeneGo, Inc., a leading provider of software and databases for systems biology and pathway analysis, today announced that the University of Cardiff has become a certified GeneGo Center of Excellence. Cardiff University researchers will have access to GeneGo’s MetaCore, training and advanced support. They will be able to leverage their partner relationship with GeneGo to provide a pathway analysis environment for all the university’s researchers.

“We will be using MetaCore to support a range of researchers across Cardiff University who are using our transcriptomics core facility, including major programs in cancer research, infection and immunity, and neuropsychiatric disease,” said Professor David Kipling, Director of Operations of Central Biotechnology Services.

“We are pleased to add our first GeneGo Center of Excellence in Wales,” said Julie Bryant, Vice President of Business Development at GeneGo. “We look forward to working with David’s group and watching advances they make and publications using MetaCore.”

### **About GeneGo, Inc.**

GeneGo, Inc. develops systems biology technology such as compound based [pathway analysis](#), cheminformatics & [bioinformatics software](#) for life science research. The original computational MetaDiscovery™ platform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, [proteomics](#), metabolomics, microRNA assays and other phenotypic data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of curated biological pathways and networks. GeneGo’s flagship product, MetaCore 5.3™, assists pharmaceutical scientists in the areas of target selection and validation, [data mining](#) in biology, identification of biomarkers for disease states and toxicology. The second product, MetaDrug 5.3™ is designed for prediction of human metabolism, toxicity and biological effects for novel small molecules compounds. MetaBase™ represents the knowledge base for MetaCore.

For more information, please visit the company's web site at [www.genego.com](http://www.genego.com).